Assessment Status | Rapid Review Complete |
HTA ID | 23071 |
Drug | Ritlecitinib |
Brand | Litfulo® |
Indication | For the treatment of severe alopecia areata in adults and adolescents 12 years of age and older. |
Assessment Process | |
Rapid review commissioned | 27/11/2023 |
Rapid review resubmission required | 11/12/2023 |
Rapid review completed | 22/12/2023 |
Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ritlecitinib compared with the current standard of care. |